BenzingaOctober 26, 2026 at 5:08 AM NYYesterday
Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test
Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
